The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia

The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML). Moreover, fms like tyrosine kinase 3 (FLT3) growth factor signaling pathways i...

Full description

Bibliographic Details
Main Authors: Katja Seipel, Miguel A. T. Marques, Corinne Sidler, Beatrice U. Mueller, Thomas Pabst
Format: Article
Language:English
Published: MDPI AG 2018-05-01
Series:Cancers
Subjects:
acute myeloid leukemia (AML)
FMS like tyrosine kinase 3 (FLT3)
tumor suppressor p53 (TP53)
mouse double minute 2 homolog (MDM2)
mitogen-activated protein kinase kinase (MEK
MAP2K
MAPKK)
Online Access:http://www.mdpi.com/2072-6694/10/6/170

Internet

http://www.mdpi.com/2072-6694/10/6/170

Similar Items